Therapeutic uses of FGFs

Seminars in Cell and Developmental Biology

Volumn 53, Issue , 2016, Pages 144-154

  Zhang, Jun ^a   Li, Yang ^a  

^a AMGEN INC   (United States)

Author keywords

Antibody; FGF; FGFR; Kinase inhibitor; Klotho; Therapy

Indexed keywords

ADIPONECTIN; ANTIBODY; ANTINEOPLASTIC AGENT; BILE ACID; CHEMOKINE; CYTOKINE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 10; FIBROBLAST GROWTH FACTOR 16; FIBROBLAST GROWTH FACTOR 18; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 21; FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FIBROBLAST GROWTH FACTOR RECEPTOR 4; KERATINOCYTE GROWTH FACTOR; KLOTHO PROTEIN; LIGAND; MONOCLONAL ANTIBODY; NUCLEIC ACID; PHOSPHATE; PROTEIN TYROSINE KINASE INHIBITOR; UNINDEXED DRUG; VASCULOTROPIN; VITAMIN D;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER THERAPY; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DRUG EFFICACY; DRUG INDICATION; EMBRYO DEVELOPMENT; GENE MUTATION; GENETIC DISORDER; HUMAN; METABOLIC SYNDROME X; NEOPLASM; NONHUMAN; OBESITY; PHOSPHATE METABOLISM; REVIEW; SIGNAL TRANSDUCTION; TISSUE REPAIR; WOUND HEALING; WOUND HEALING IMPAIRMENT; ANIMAL; BIOLOGICAL MODEL; DRUG EFFECTS; REGENERATION;

ANIMALS; FIBROBLAST GROWTH FACTORS; HUMANS; MODELS, BIOLOGICAL; REGENERATION; SIGNAL TRANSDUCTION; WOUND HEALING;

EID: 84941781254     PISSN: 10849521     EISSN: 10963634     Source Type: Journal    
DOI: 10.1016/j.semcdb.2015.09.007     Document Type: Review

References (217)

1. Itoh N., Ornitz D.M. Evolution of the Fgf and Fgfr gene families. Trends Genet. 2004, 20:563-569.
2. Mohammadi M., Olsen S.K., Ibrahimi O.A. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev. 2005, 16:107-137.
3. Eswarakumar V.P., Lax I., Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 2005, 16:139-149.
4. Flaumenhaft R., Moscatelli D., Rifkin D.B. Heparin and heparan sulfate increase the radius of diffusion and action of basic fibroblast growth factor. J. Cell Biol. 1990, 111:1651-1659.
5. Kurosu H., Kuro-o M. The Klotho gene family and the endocrine fibroblast growth factors. Curr. Opin. Nephrol. Hypertens. 2008, 17:368-372.
6. Kurosu H., Kuro O.M. The Klotho gene family as a regulator of endocrine fibroblast growth factors. Mol. Cell. Endocrinol. 2009, 299:72-78.
7. Kuro-o M. Klotho and betaKlotho. Adv. Exp. Med. Biol. 2012, 728:25-40.
8. Beenken A., Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat. Rev. Drug Discov. 2009, 8:235-253.
9. Dailey L., Ambrosetti D., Mansukhani A., Basilico C. Mechanisms underlying differential responses to FGF signaling. Cytokine Growth Factor Rev. 2005, 16:233-247.
10. Turner N., Grose R. Fibroblast growth factor signalling: from development to cancer. Nat. Rev. Cancer 2010, 10:116-129.
11. Courjal F., et al. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. Cancer Res. 1997, 57:4360-4367.
12. Weiss J., et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci. Transl. Med. 2010, 2. 62ra93.
13. Rand V., et al. Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:14344-14349.
14. Giri D., Ropiquet F., Ittmann M. Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. Clin. Cancer Res. 1999, 5:1063-1071.
15. Jackson C.C., Medeiros L.J., Miranda R.N. 8p11 myeloproliferative syndrome: a review. Hum. Pathol. 2010, 41:461-476.
16. Tchaicha J.H., et al. Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a Pan-FGFR inhibitor in a mouse model of NSCLC. Cancer Res. 2014, 74:4676-4684.
17. Dutt A., et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:8713-8717.
18. Gartside M.G., et al. Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma. Mol. Cancer Res. 2009, 7:41-54.
19. Zhao Q., et al. Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas. Clin. Cancer Res. 2013, 19:2460-2472.
20. Kunii K., et al. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival. Cancer Res. 2008, 68:2340-2348.
21. Cha J.Y., Lambert Q.T., Reuther G.W., Der C.J. Involvement of fibroblast growth factor receptor 2 isoform switching in mammary oncogenesis. Mol. Cancer Res. 2008, 6:435-445.
22. Easton D.F., et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007, 447:1087-1093.
23. Garcia-Closas M., et al. Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet. 2008, 4:e1000054.
24. Cappellen D., et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat. Genet. 1999, 23:18-20.
25. Chesi M., et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat. Genet. 1997, 16:260-264.
26. Hafner C., Vogt T., Hartmann A. FGFR3 mutations in benign skin tumors. Cell Cycle 2006, 5:2723-2728.
27. Lin B.C., Desnoyers L.R. FGF19 and cancer. Adv. Exp. Med. Biol. 2012, 728:183-194.
28. Ho H.K., et al. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. J. Hepatol. 2009, 50:118-127.
29. Spinola M., et al. FGFR4 Gly388Arg polymorphism and prognosis of breast and colorectal cancer. Oncol. Rep. 2005, 14:415-419.
30. Taylor J.G.t., et al. Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. J. Clin. Invest. 2009, 119:3395-3407.
31. Alessi P., et al. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist. Eur. Cytokine Netw. 2009, 20:225-234.
32. Ware J.A., Simons M. Angiogenesis in ischemic heart disease. Nat. Med. 1997, 3:158-164.
33. Yanagisawa-Miwa A., et al. Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science 1992, 257:1401-1403.
34. Pardo O.E., et al. FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2. EMBO J. 2006, 25:3078-3088.
35. Hanada K., Perry-Lalley D.M., Ohnmacht G.A., Bettinotti M.P., Yang J.C. Identification of fibroblast growth factor-5 as an overexpressed antigen in multiple human adenocarcinomas. Cancer Res. 2001, 61:5511-5516.
36. Hu M.C., et al. FGF-18, a novel member of the fibroblast growth factor family, stimulates hepatic and intestinal proliferation. Mol. Cell. Biol. 1998, 18:6063-6074.
37. Kin M., et al. Basic fibroblast growth factor regulates proliferation and motility of human hepatoma cells by an autocrine mechanism. J. Hepatol. 1997, 27:677-687.
38. Presta M., et al. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 2005, 16:159-178.
39. Nicholes K., et al. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am. J. Pathol. 2002, 160:2295-2307.
40. Pai R., et al. Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling. Cancer Res. 2008, 68:5086-5095.
41. Desnoyers L.R., et al. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene 2008, 27:85-97.
42. Sawey E.T., et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell 2011, 19:347-358.
43. Huynh H., et al. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin. Cancer Res. 2008, 14:6146-6153.
44. Schlumberger M., et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N. Engl. J. Med. 2015, 372:621-630.
45. Wong A.L., et al. Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib. J. Transl. Med. 2015, 13:57.
46. Gozgit J.M., et al. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol. Cancer Ther. 2012, 11:690-699.
47. Chase A., Grand F.H., Cross N.C. Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. Blood 2007, 110:3729-3734.
48. Konecny G.E., et al. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells. Mol. Cancer Ther. 2013, 12:632-642.
49. Dhillon S., Nintedanib: A review of its use as second-line treatment in adults with advanced non-small cell lung cancer of adenocarcinoma histology. Target Oncol. 2015.
50. Spraggs C.F., et al. Different effects of the BIM deletion polymorphism on treatment of solid tumors by the tyrosine kinase inhibitors (TKI) pazopanib, sunitinib, and lapatinib. Ann. Oncol. 2015.
51. Ikeda M., et al. Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma. Invest. New Drugs 2014, 32:928-936.
52. Diamond J.R., et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors. Clin. Cancer Res. 2011, 17:849-860.
53. Bello E., et al. E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011, 71:1396-1405.
54. Hong D.S., et al. First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-kappaBeta and p70s6k, in patients with advanced solid tumors. Invest. New Drugs 2014, 32:1204-1212.
55. Dimitroff C.J., et al. Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD166285 and PD173074: implications for combination treatment with photodynamic therapy. Invest. New Drugs 1999, 17:121-135.
56. Lei J., et al. TC-1 overexpression promotes cell proliferation in human non-small cell lung cancer that can be inhibited by PD173074. PLoS ONE 2014, 9:e100075.
57. Grand E.K., Chase A.J., Heath C., Rahemtulla A., Cross N.C. Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074. Leukemia 2004, 18:962-966.
58. Escudier B., et al. Phase II results of Dovitinib (TKI258) in patients with metastatic renal cell cancer. Clin. Cancer Res. 2014, 20:3012-3022.
59. Caglevic C., et al. Nintedanib in non-small cell lung cancer: from preclinical to approval. Ther. Adv. Respir. Dis. 2015.
60. Dizon D.S., et al. A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol. Oncol. 2014, 135:441-445.
61. Reck M., Heigener D., Reinmuth N. Nintedanib for the treatment of patients with advanced non-small-cell lung cancer. Expert Rev. Clin. Pharmacol. 2014, 7:579-590.
62. Quintela-Fandino M., et al. Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010/GEICAM-2010-10 study). Br. J. Cancer 2014, 111:1060-1064.
63. Powell M.A., et al. A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol. Oncol. 2014, 135:38-43.
64. Cabanillas M.E., et al. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment. Cancer 2015.
65. Katoh M., Nakagama H. FGF receptors: cancer biology and therapeutics. Med. Res. Rev. 2014, 34:280-300.
66. Gavine P.R., et al. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 2012, 72:2045-2056.
67. Guagnano V., et al. Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamin o]-pyrimidin-4-yl-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J. Med. Chem. 2011, 54:7066-7083.
68. Zhao G., et al. A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models. Mol. Cancer Ther. 2011, 10:2200-2210.
69. Ochiiwa H., et al. TAS-120, a highly potent and selective irreversible FGFR inhibitor, is effective in tumors harboring various FGFR gene abnormalities. Mol. Cancer Ther. 2013, 12:A270.
70. Dransfield D., et al. ARQ 087, a multi-tyrosine kinase inhibitor with potent in vitro and in vivo activity in FGFR2 driven models. Mol. Cancer Ther. 2013, 12:A278.
71. Andre F., Cortes J. Rationale for targeting fibroblast growth factor receptor signaling in breast cancer. Breast Cancer Res. Treat. 2015, 150:1-8.
72. Hagel M., et al. First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated FGFR4 signaling pathway. Cancer Discov. 2015, 5:424-437.
73. Xie L., et al. FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. Clin. Cancer Res. 2013, 19:2572-2583.
74. Liu L., et al. Reductions in myeloid-derived suppressor cells and lung metastases using AZD4547 treatment of a metastatic murine breast tumor model. Cell. Physiol. Biochem. 2014, 33:633-645.
75. Guagnano V., et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2012, 2:1118-1133.
76. Yashiro M., et al. Synergistic antitumor effects of FGFR2 inhibitor with 5-fluorouracil on scirrhous gastric carcinoma. Int. J. Cancer 2010, 126:1004-1016.
77. Lieu C., Heymach J., Overman M., Tran H., Kopetz S. Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis. Clin. Cancer Res. 2011, 17:6130-6139.
78. Bai A., et al. GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling. Cancer Res. 2010, 70:7630-7639.
79. Zhao W.M., et al. Monoclonal antibodies to fibroblast growth factor receptor 2 effectively inhibit growth of gastric tumor xenografts. Clin. Cancer Res. 2010, 16:5750-5758.
80. Qing J., et al. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J. Clin. Invest. 2009, 119:1216-1229.
81. Bumbaca D., et al. Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4. MAbs 2011, 3:376-386.
82. Shimada N., et al. A neutralizing anti-fibroblast growth factor 8 monoclonal antibody shows potent antitumor activity against androgen-dependent mouse mammary tumors in vivo. Clin. Cancer Res. 2005, 11:3897-3904.
83. Maruyama-Takahashi K., et al. A neutralizing anti-fibroblast growth factor (FGF) 8 monoclonal antibody shows anti-tumor activity against FGF8b-expressing LNCaP xenografts in androgen-dependent and -independent conditions. Prostate 2008, 68:640-650.
84. Harding T.C., et al. Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer. Sci. Transl. Med. 2013, 5. 178ra139.
85. Katoh M. RNA technology targeted to the WNT signaling pathway. Cancer Biol. Ther. 2008, 7:275-277.
86. Stock A., Kuzis K., Woodward W.R., Nishi R., Eckenstein F.P. Localization of acidic fibroblast growth factor in specific subcortical neuronal populations. J. Neurosci. 1992, 12:4688-4700.
87. Guest J.D., et al. Influence of IN-1 antibody and acidic FGF-fibrin glue on the response of injured corticospinal tract axons to human Schwann cell grafts. J. Neurosci. Res. 1997, 50:888-905.
88. Cuevas P., Carceller F., Gimenez-Gallego G. Acidic fibroblast growth factor prevents death of spinal cord motoneurons in newborn rats after nerve section. Neurol. Res. 1995, 17:396-399.
89. Lin P.H., Cheng H., Huang W.C., Chuang T.Y. Spinal cord implantation with acidic fibroblast growth factor as a treatment for root avulsion in obstetric brachial plexus palsy. J. Chin. Med. Assoc. 2005, 68:392-396.
90. Lin P.H., Chuang T.Y., Liao K.K., Cheng H., Shih Y.S. Functional recovery of chronic complete idiopathic transverse myelitis after administration of neurotrophic factors. Spinal Cord. 2006, 44:254-257.
91. Murakami S., et al. Regeneration of periodontal tissues by basic fibroblast growth factor. J. Periodontal Res. 1999, 34:425-430.
92. Takayama S., Murakami S., Shimabukuro Y., Kitamura M., Okada H. Periodontal regeneration by FGF-2 (bFGF) in primate models. J. Dent. Res. 2001, 80:2075-2079.
93. Murakami S., et al. Recombinant human basic fibroblast growth factor (bFGF) stimulates periodontal regeneration in class II furcation defects created in beagle dogs. J. Periodontal Res. 2003, 38:97-103.
94. Kitamura M., et al. Periodontal tissue regeneration using fibroblast growth factor-2: randomized controlled phase II clinical trial. PLoS ONE 2008, 3:e2611.
95. Meier K., Nanney L.B. Emerging new drugs for wound repair. Expert Opin. Emerg. Drugs 2006, 11:23-37.
96. Finch P.W., Pricolo V., Wu A., Finkelstein S.D. Increased expression of keratinocyte growth factor messenger RNA associated with inflammatory bowel disease. Gastroenterology 1996, 110:441-451.
97. Guo L., Degenstein L., Fuchs E. Keratinocyte growth factor is required for hair development but not for wound healing. Genes Dev. 1996, 10:165-175.
98. Werner S. Keratinocyte growth factor: a unique player in epithelial repair processes. Cytokine Growth Factor Rev. 1998, 9:153-165.
99. Han D.S., et al. Keratinocyte growth factor-2 (FGF-10) promotes healing of experimental small intestinal ulceration in rats. Am. J. Physiol. Gastrointest. Liver Physiol. 2000, 279:G1011-G1022.
100. Miceli R., et al. Efficacy of keratinocyte growth factor-2 in dextran sulfate sodium-induced murine colitis. J. Pharmacol. Exp. Ther. 1999, 290:464-471.
101. Sandborn W.J., et al. Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Aliment. Pharmacol. Ther. 2003, 17:1355-1364.
102. Freytes C.O., et al. Phase I/II randomized trial evaluating the safety and clinical effects of repifermin administered to reduce mucositis in patients undergoing autologous hematopoietic stem cell transplantation. Clin. Cancer Res. 2004, 10:8318-8324.
103. Xia J.X., et al. Effect of FGF10 monoclonal antibody on psoriasis-like model in guinea pigs. Int. J. Clin. Exp. Pathol. 2014, 7:2219-2228.
104. Ohbayashi N., et al. FGF18 is required for normal cell proliferation and differentiation during osteogenesis and chondrogenesis. Genes Dev. 2002, 16:870-879.
105. Ellsworth J.L., et al. Fibroblast growth factor-18 is a trophic factor for mature chondrocytes and their progenitors. Osteoarthritis Cartilage 2002, 10:308-320.
106. Whitsett J.A., et al. Fibroblast growth factor 18 influences proximal programming during lung morphogenesis. J. Biol. Chem. 2002, 277:22743-22749.
107. Davidson D., et al. Fibroblast growth factor (FGF) 18 signals through FGF receptor 3 to promote chondrogenesis. J. Biol. Chem. 2005, 280:20509-20515.
108. Moore E.E., et al. Fibroblast growth factor-18 stimulates chondrogenesis and cartilage repair in a rat model of injury-induced osteoarthritis. Osteoarthritis Cartilage 2005, 13:623-631.
109. Howard D., Wardale J., Guehring M.H., Henson F. Delivering rhFGF-18 via a bilayer collagen membrane to enhance microfracture treatment of chondral defects in a large animal model. J. Orthop. Res. 2015.
110. Lohmander L.S., et al. Intraarticular sprifermin (recombinant human fibroblast growth factor 18) in knee osteoarthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2014, 66:1820-1831.
111. Ohuchi H., et al. FGF10 acts as a major ligand for FGF receptor 2 IIIb in mouse multi-organ development. Biochem. Biophys. Res. Commun. 2000, 277:643-649.
112. Bhushan A., et al. Fgf10 is essential for maintaining the proliferative capacity of epithelial progenitor cells during early pancreatic organogenesis. Development 2001, 128:5109-5117.
113. Konishi M., Mikami T., Yamasaki M., Miyake A., Itoh N. Fibroblast growth factor-16 is a growth factor for embryonic brown adipocytes. J. Biol. Chem. 2000, 275:12119-12122.
114. Tomlinson E., et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 2002, 143:1741-1747.
115. Kharitonenkov A., et al. FGF-21 as a novel metabolic regulator. J. Clin. Invest. 2005, 115:1627-1635.
116. Fu L., et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 2004, 145:2594-2603.
117. Wu X., et al. Separating mitogenic and metabolic activities of fibroblast growth factor 19 (FGF19). Proc. Natl. Acad. Sci. U. S. A. 2010, 107:14158-14163.
118. Kharitonenkov A., et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 2007, 148:774-781.
119. Coskun T., et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008, 149:6018-6027.
120. Xu J., et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009, 58:250-259.
121. Inagaki T., et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab. 2007, 5:415-425.
122. Veniant M., et al. Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys. Endocrinology 2012, 153.
123. Gimeno R.E., Moller D.E. FGF21-based pharmacotherapy - potential utility for metabolic disorders. Trends Endocrinol. Metab. 2014, 25:303-311.
124. Kharitonenkov A., Adams A.C. Inventing new medicines: the FGF21 story. Mol. Metab. 2014, 3:221-229.
125. Owen B.M., Mangelsdorf D.J., Kliewer S.A. Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21. Trends Endocrinol. Metab. 2015, 26:22-29.
126. Wu X., et al. FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation. J. Biol. Chem. 2010, 285:5165-5170.
127. French D.M., et al. Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PLoS ONE 2012, 7:e36713.
128. Wu X., Li Y. Therapeutic utilities of fibroblast growth factor 19. Expert Opin. Ther. Targets 2011, 15:1307-1316.
129. Ge H., et al. Characterization of a FGF19 variant with altered receptor specificity revealed a central role for FGFR1c in the regulation of glucose metabolism. PLoS ONE 2012, 7:e33603.
130. Wu A.L., et al. FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways. PLoS ONE 2011, 6:e17868.
131. Luo J., et al. A nontumorigenic variant of FGF19 treats cholestatic liver diseases. Sci. Transl. Med. 2014, 6:247ra100.
132. Zhang Y., et al. The starvation hormone, fibroblast growth factor-21, extends lifespan in mice. Elife 2012, 1:e00065.
133. Zhang J., Li Y. Fibroblast growth factor 21, the endocrine FGF pathway and novel treatments for metabolic syndrome. Drug Discov. Today 2014, 19:579.
134. Kharitonenkov A., et al. Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319. PLoS ONE 2013, 8:e58575.
135. Adams A.C., et al. LY2405319, an engineered FGF21 variant, improves the metabolic status of diabetic monkeys. PLoS ONE 2013, 8:e65763.
136. Gaich G., et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab. 2013, 18:333-340.
137. Huang Z., et al. A better anti-diabetic recombinant human fibroblast growth factor 21 (rhFGF21) modified with polyethylene glycol. PLoS ONE 2011, 6:e20669.
138. Mu J., et al. FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents. Diabetes 2012.
139. Xu J., et al. Polyethylene glycol modified FGF21 engineered to maximize potency and minimize vacuole formation. Bioconjug. Chem. 2013, 10.1021/bc300603k.
140. Hecht R., et al. Rationale-based engineering of a potent long-acting FGF21 analog for the treatment of type 2 diabetes. PLoS ONE 2012, 7:e49345.
141. Huang J., et al. Development of a novel long-acting antidiabetic FGF21 mimetic by targeted conjugation to a scaffold antibody. J. Pharmacol. Exp. Ther. 2013, 346:270-280.
142. Wu A.L., et al. Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1. Sci. Transl. Med. 2011, 3. 113ra126.
143. Foltz I.N., et al. Treating diabetes and obesity with an FGF21-mimetic antibody activating the betaKlotho/FGFR1c receptor complex. Sci. Transl. Med. 2012, 4. 162ra153.
144. Ding X., et al. betaKlotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell Metab. 2012, 16:387-393.
145. Adams A.C., Cheng C.C., Coskun T., Kharitonenkov A. FGF21 requires betaklotho to act in vivo. PLoS ONE 2012, 7:e49977.
146. Adams A.C., et al. The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue. Mol. Metab. 2013, 2:31.
147. Smith R., et al. FGF21 can be mimicked in vitro and in vivo by a novel anti-FGFR1c/beta-klotho bispecific protein. PLoS ONE 2013, 8:e61432.
148. Jonker J.W., et al. A PPARgamma-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis. Nature 2012, 485:391-394.
149. Suh J.M., et al. Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer. Nature 2014, 513:436-439.
150. Goetz R., et al. Conversion of a paracrine fibroblast growth factor into an endocrine fibroblast growth factor. J. Biol. Chem. 2012, 287:29134-29146.
151. Inagaki T., et al. Inhibition of growth hormone signaling by the fasting-induced hormone FGF21. Cell Metab. 2008, 8:77-83.
152. Wu S., Levenson A., Kharitonenkov A., De Luca F. Fibroblast growth factor 21 (FGF21) inhibits chondrocyte function and growth hormone action directly at the growth plate. J. Biol. Chem. 2012, 287:26060-26067.
153. Wei W., et al. Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor gamma. Proc. Natl. Acad. Sci. U. S. A. 2012.
154. Bookout A.L., et al. FGF21 regulates metabolism and circadian behavior by acting on the nervous system. Nat. Med. 2013, 19:1147-1152.
155. Dutchak P.A., et al. Fibroblast growth factor-21 regulates PPARgamma activity and the antidiabetic actions of thiazolidinediones. Cell 2012, 148:556-567.
156. Owen B.M., et al. FGF21 contributes to neuroendocrine control of female reproduction. Nat. Med. 2013, 19:1153-1156.
157. Wu X., et al. Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:14379-14384.
158. Huang X., et al. FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet induced fatty liver. Diabetes 2007, 56:2501-2510.
159. Ge H., et al. Fibroblast growth factor receptor 4 (FGFR4) deficiency improves insulin resistance and glucose metabolism under diet-induced obesity conditions. J. Biol. Chem. 2014, 289:30470-30480.
160. Thomas C., Pellicciari R., Pruzanski M., Auwerx J., Schoonjans K. Targeting bile-acid signalling for metabolic diseases. Nat. Rev. Drug Discov. 2008, 7:678-693.
161. Yu X.X., et al. Peripheral reduction of FGFR4 with antisense oligonucleotides increases metabolic rate and lowers adiposity in diet-induced obese mice. PLoS ONE 2013, 8:e66923.
162. Chiang J.Y. Bile acid metabolism and signaling. Compr. Physiol. 2013, 3:1191-1212.
163. Lee F.Y., Lee H., Hubbert M.L., Edwards P.A., Zhang Y. FXR, a multipurpose nuclear receptor. Trends Biochem. Sci. 2006, 31:572-580.
164. Mencarelli A., Fiorucci S. FXR an emerging therapeutic target for the treatment of atherosclerosis. J. Cell. Mol. Med. 2010, 14:79-92.
165. Jones S.A. Physiology of FGF15/19. Adv. Exp. Med. Biol. 2012, 728:171-182.
166. Angelin B., Larsson T.E., Rudling M. Circulating fibroblast growth factors as metabolic regulators - a critical appraisal. Cell Metab. 2012, 16:693-705.
167. Walters J.R. Bile acid diarrhoea and FGF19: new views on diagnosis, pathogenesis and therapy. Nat. Rev. Gastroenterol. Hepatol. 2014, 11:426-434.
168. Choi M., et al. Identification of a hormonal basis for gallbladder filling. Nat. Med. 2006, 12:1253-1255.
169. Zweers S.J., et al. The human gallbladder secretes fibroblast growth factor 19 into bile: towards defining the role of fibroblast growth factor 19 in the enterobiliary tract. Hepatology 2012, 55:575-583.
170. Luo L., Luo F., Wang T. Cynomolgus monkey gallbladder bile contains high concentrations of fibroblast growth factor 19. Hepatology 2014, 59:732-733.
171. Holt J.A., et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 2003, 17:1581-1591.
172. Song K.H., Li T., Owsley E., Strom S., Chiang J.Y. Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression. Hepatology 2009, 49:297-305.
173. Schaap F.G., van der Gaag N.A., Gouma D.J., Jansen P.L. High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology 2009, 49:1228-1235.
174. Pai R., et al. Antibody-mediated inhibition of fibroblast growth factor 19 results in increased bile acids synthesis and ileal malabsorption of bile acids in cynomolgus monkeys. Toxicol. Sci. 2012, 126:446-456.
175. Rastegar A. New concepts in pathogenesis of renal hypophosphatemic syndromes. Iran. J. Kidney Dis. 2009, 3:1-6.
176. Gaasbeek A., Meinders A.E. Hypophosphatemia: an update on its etiology and treatment. Am. J. Med. 2005, 118:1094-1101.
177. Martin A., Quarles L.D. Evidence for FGF23 involvement in a bone-kidney axis regulating bone mineralization and systemic phosphate and vitamin D homeostasis. Adv. Exp. Med. Biol. 2012, 728:65-83.
178. Razzaque M.S. FGF23, klotho and vitamin D interactions: What have we learned from in vivo mouse genetics studies?. Adv. Exp. Med. Biol. 2012, 728:84-91.
179. Silver J., Naveh-Many T. FGF23 and the parathyroid. Adv. Exp. Med. Biol. 2012, 728:92-99.
180. Shimada T., et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J. Bone Miner. Res. 2004, 19:429-435.
181. Fukumoto S. Physiological regulation and disorders of phosphate metabolism - pivotal role of fibroblast growth factor 23. Intern. Med. 2008, 47:337-343.
182. Liu S., et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J. Am. Soc. Nephrol. 2006, 17:1305-1315.
183. Ben-Dov I.Z., et al. The parathyroid is a target organ for FGF23 in rats. J. Clin. Invest. 2007, 117:4003-4008.
184. Krajisnik T., et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J. Endocrinol. 2007, 195:125-131.
185. Kuro-o M., et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997, 390:45-51.
186. Shimada T., et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J. Clin. Invest. 2004, 113:561-568.
187. Sitara D., et al. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol. 2004, 23:421-432.
188. Consortium A. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat. Genet. 2000, 26:345-348.
189. Shimada T., et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:6500-6505.
190. Jonsson K.B., et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N. Engl. J. Med. 2003, 348:1656-1663.
191. Hoffman W.H., Jueppner H.W., Deyoung B.R., O'Dorisio M.S., Given K.S. Elevated fibroblast growth factor-23 in hypophosphatemic linear nevus sebaceous syndrome. Am. J. Med. Genet. A 2005, 134:233-236.
192. Farrow E.G., et al. Extended mutational analyses of FGFR1 in osteoglophonic dysplasia. Am. J. Med. Genet. A 2006, 140:537-539.
193. Riminucci M., et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J. Clin. Invest. 2003, 112:683-692.
194. Yamazaki Y., et al. Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J. Bone Miner. Res. 2008, 23:1509-1518.
195. Aono Y., et al. Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. J. Bone Miner. Res. 2009, 24:1879-1888.
196. Carpenter T.O., et al. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J. Clin. Invest. 2014, 124:1587-1597.
197. Goetz R., et al. Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:407-412.
198. Bhan I., et al. Post-transplant hypophosphatemia: tertiary 'hyper-phosphatoninism'?. Kidney Int. 2006, 70:1486-1494.
199. Slavin R.E., Wen J., Kumar D., Evans E.B. Familial tumoral calcinosis. A clinical, histopathologic, and ultrastructural study with an analysis of its calcifying process and pathogenesis. Am. J. Surg. Pathol. 1993, 17:788-802.
200. Topaz O., et al. Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat. Genet. 2004, 36:579-581.
201. Benet-Pages A., Orlik P., Strom T.M., Lorenz-Depiereux B. An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum. Mol. Genet. 2005, 14:385-390.
202. Ichikawa S., et al. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J. Clin. Invest. 2007, 117:2684-2691.
203. Wu A.L., et al. Antibody-mediated activation of FGFR1 induces FGF23 production and hypophosphatemia. PLoS ONE 2013, 8:e57322.
204. Komaba H., Fukagawa M. FGF23-parathyroid interaction: implications in chronic kidney disease. Kidney Int. 2010, 77:292-298.
205. Razzaque M.S. The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis. Nat. Rev. Endocrinol. 2009, 5:611-619.
206. Wahl P., Wolf M. FGF23 in chronic kidney disease. Adv. Exp. Med. Biol. 2012, 728:107-125.
207. Gutierrez O.M., et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N. Engl. J. Med. 2008, 359:584-592.
208. Isakova T., et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011, 79:1370-1378.
209. Shimada T., et al. Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J. Clin. Endocrinol. Metab. 2010, 95:578-585.
210. Faul C., et al. FGF23 induces left ventricular hypertrophy. J. Clin. Invest. 2011, 121:4393-4408.
211. Itoh N., Ohta H. Pathophysiological roles of FGF signaling in the heart. Front. Physiol. 2013, 4:247.
212. Unger E.F., et al. Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris. Am. J. Cardiol. 2000, 85:1414-1419.
213. Ruel M., et al. Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein. J. Thorac. Cardiovasc. Surg. 2002, 124:28-34.
214. Eisenberger M.A., et al. Suramin, an active drug for prostate cancer: interim observations in a phase I trial. J. Natl. Cancer Inst. 1993, 85:611-621.
215. Ahles T.A., et al. Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480. Cancer 2004, 101:2202-2208.
216. Spielberger R., et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N. Engl. J. Med. 2004, 351:2590-2598.
217. Camacho R.C., Zafian P.T., Achanfuo-Yeboah J., Manibusan A., Berger J.P. Pegylated Fgf21 rapidly normalizes insulin-stimulated glucose utilization in diet-induced insulin resistant mice. Eur. J. Pharmacol. 2013, 715:41-45.